A medical device can clear FDA and still fail to win over the physicians who would use it. We call the distance between a device's clinical promise and its real uptake the "Adoption Gap", and it is easy to under-weight in an acquisition model.
A device can have FDA clearance, manufacturing excellence, and even strong initial market interest. But if physicians don't adopt it in the numbers the acquirer projected, the revenue assumptions in the deal model fail. The gap may not show up until well after close.
Understanding the Adoption Gap
Clinical adoption isn't simply a function of clinical efficacy. Physicians make adoption decisions based on a complex web of factors: workflow integration, learning curve, reimbursement reliability, peer influence, and institutional inertia. A device that works better than alternatives doesn't automatically win market share if it disrupts established clinical workflows or requires significant retraining.
When an acquired device underperforms, adoption assumptions are one of the first places to look: forecasts built on trial results can run well ahead of how practicing physicians actually take up a new device.
Three Illustrative Adoption Failure Modes
The three cases below are illustrative composites, not named companies; the figures in them are invented to show each pattern.
Mode 1: The Workflow Mismatch
A vascular device company was acquired based on superior clinical outcomes in a controlled trial. However, the device required a 15-minute longer procedure time and introduced three new steps into the OR workflow. Surgeons acknowledged the superiority but weren't willing to adjust their practices for marginal benefit. Adoption plateaued at 8% of the addressable market.
The acquirer had invested significantly in manufacturing capacity assuming 35% adoption. The resulting excess capacity and inventory write-downs led to a goodwill impairment within two years.
Mode 2: The Reimbursement Trap
A diagnostic platform achieved rapid adoption among early adopters (20% penetration in first year). However, CPT code approval took three years longer than anticipated. During that period, reimbursement remained uncertain, and many hospital systems paused purchasing. When the code finally came, adoption had plateaued and competitors had filled the gap.
Mode 3: The Competitive Headwind
An acquired device had first-mover advantage but faced rapid competitive response. The acquirer underestimated competitor willingness to accept lower margins to maintain market share. Within two years, the market had fragmented into three competing standards, and physician adoption of any single solution dropped below profitability thresholds.
Red Flags in Adoption Due Diligence
How to Assess Adoption Risk in M&A Due Diligence
1. Conduct Independent Physician Interviews
Don't rely on reference accounts selected by the target company. Recruit an independent sample of potential practitioners, including skeptics and non-adopters. Ask specific workflow questions: How many minutes longer is the procedure? How many training sessions would surgeons need? Would this require changes to facility infrastructure?
2. Compare Adoption Assumptions With Real Comparables
Look at adoption trajectories for similar devices in similar specialties. A cardiac device adoption curve looks fundamentally different from an orthopedic device curve. Compare your target's adoption projections against historical S-curve patterns. If the trajectory is steeper than comparable devices, understand why.
3. Separate Technical Adoption from Economic Adoption
A device can be technically adopted (physicians know how to use it) but economically unsuccessful (insufficient volumes at profitable prices). Reimbursement assumptions should be stress-tested against payer willingness to pay and volume requirements for profitability.
4. Assess Institutional Barriers
Healthcare systems have strong organizational inertia. Even if individual physicians prefer a new device, hospital purchasing committees may resist inventory expansion or capital investment in new equipment. Understanding hospital formulary processes and group purchasing organization (GPO) dynamics is critical.
5. Stress-Test the Adoption Assumptions
Ask how the deal case holds up if adoption is materially slower than the target's forecast, and which assumptions drive the difference.
The Post-Acquisition Reality
Adoption gaps are particularly dangerous in M&A because they compound other integration challenges. The acquirer is managing cultural integration, systems consolidation, and personnel decisions simultaneously. Adoption shortfalls often aren't recognized until the first quarterly close, at which point corrective action is constrained by organizational bandwidth.
Treating adoption as a primary question, rather than a line in the financial forecast, gives an acquirer something to plan around after close: resources for adoption, work with clinical leaders, and room to adjust positioning or reimbursement strategy if early uptake differs from the plan.
Bottom Line
Clinical adoption risk is easy to under-weight in medical device M&A. A technically superior device with strong regulatory status and capable management can still fail if adoption barriers aren't properly understood pre-acquisition. Thorough adoption due diligence—focusing on workflow integration, reimbursement clarity, and realistic physician behavior modeling—gives an acquirer a clearer view before close.
References
- Denise P. Clarke, MedDevice Online. "From 'Approved' To 'Covered' — What Medical Device Companies Need to Know." May 31, 2017. meddeviceonline.com
- NIH SEED Innovator Support Team. "Reimbursement Knowledge Guide for Medical Devices." January 2024. seed.nih.gov
- "Acceptance and Resistance of New Digital Technologies in Medicine: Qualitative Study." PubMed Central. ncbi.nlm.nih.gov
Need Adoption Risk Analysis for Your Portfolio?
Vantage full reports assemble the public record on a company, cite factual claims to their sources, and are reviewed by Arvind Ravinutala, MD, and Aswini Ravinutala, BME. Start with a free 20-minute call.